CN102670705A - Traditional Chinese medicine composition and application thereof - Google Patents

Traditional Chinese medicine composition and application thereof Download PDF

Info

Publication number
CN102670705A
CN102670705A CN2012101460639A CN201210146063A CN102670705A CN 102670705 A CN102670705 A CN 102670705A CN 2012101460639 A CN2012101460639 A CN 2012101460639A CN 201210146063 A CN201210146063 A CN 201210146063A CN 102670705 A CN102670705 A CN 102670705A
Authority
CN
China
Prior art keywords
chinese medicine
medicine composition
calculus
active ingredient
renal
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN2012101460639A
Other languages
Chinese (zh)
Inventor
张自成
郑华贵
金鑫
苏正勤
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Zheng Huagui
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Priority to CN2012101460639A priority Critical patent/CN102670705A/en
Publication of CN102670705A publication Critical patent/CN102670705A/en
Pending legal-status Critical Current

Links

Landscapes

  • Medicines Containing Plant Substances (AREA)

Abstract

The invention discloses a traditional Chinese medicine composition, which comprises a treatment active ingredient and a pharmaceutically available carrier, wherein the treatment active ingredient is prepared from the following components in weight ratio: 20-60 parts of lysimachia christinae hance and 20-60 parts of bidens pilosalinn. Proved by clinical application, the traditional Chinese medicine composition has the outstanding characteristics that renal calculi can be rapidly removed and are not easy to relapse, tetany can be resolved and pains can be relieved, and renal colic can be rapidly relieved after the traditional Chinese medicine composition is orally taken.

Description

A kind of Chinese medicine composition and uses thereof
Technical field
The present invention relates to a kind of Chinese medicine composition that can be used as renal calculus medicine or renal calculus prophylactic agent and uses thereof.
Background technology
Along with the change with dietary habit that improves constantly of living standards of the people, the sickness rate of China's urinary system calculus is in obvious propradation.Calculus often stays in kidney, ureter, bladder and causes renal calculus, ureteral calculus, vesical calculus, and is wherein common with renal calculus.Renal calculus mostly occurred in the middle prime of life, and the male is more than the Ms.Clinical manifestation is varied, and renal calculus maybe long-term existence and asymptomatic, particularly bigger calculus.Less calculus range of activity is big, when microlith gets into UPJ or ureter, causes the wriggling that ureter is violent, discharges to impel calculus, so angor and hematuria occur.40%~50% patient is the history of pain of gapped outbreak.Pain often is positioned at waist and abdominal part, and majority is paroxysmal, also can be constant pain.Renal colic is serious lancinating pain, outbreak suddenly often, and pain often is radiated to hypogastric region, groin or burst inboard.When renal colic is serious, pale complexion, whole body is in a cold sweat, thready pulse and speed, even blood pressure drops are collapse, simultaneously with feel sick, vomiting, abdominal distention constipation.During the angor outbreak, hypourocrinia after angor is alleviated, can have the polyuria phenomenon.Hematuria is another cardinal symptom of renal calculus.During pain, often occur together gross hematuria or microscopic hematuria, in the majority with the latter, hematuria can increase the weight of after the physical exertion.The common complication of renal calculus is to block and infection, and many cases are sought medical advice because of the urinary tract infection symptom.Obstruction then can cause hydronephrosis, epigastrium or waist lump occur.
The treatment of renal calculus is main with open surgery and medicine dissolution therapy mainly.The open surgery wound is big, complication is many, and sometimes because recurrence of hepatolithiasis need go and repeatedly perform the operation and have a strong impact on renal function; Though had extracorporeal shock-wave lithotomy and some non-open operations to get the application of minimally-invasive treatment such as stone in recent years, made a lot of former miseries that need patients with surgical to exempt operation.Although extracorporeal shock-wave lithotomies etc. have brought Gospel to patient, reduced wound, the still need partner treatment of medicine of calculus behind its rubble and prevention recurrence of hepatolithiasis process, however this Western medicine medicine on the one hand is less, and is main with symptomatic treatment often, and prognosis is relatively poor.
Therefore, the practitioner begins to consider to use the Chinese medicine compound calculus, to obtain better prognosis therapeutic effect.
Herba Lysimachiae, formal name used at school: Lysimachia christinae Hance all has distribution in each province, the south of the River.Summer, Qiu Erji gather.Remove impurity, dry, cutting is given birth to and is used.Have heat-clearing and toxic substances removing, dissipating blood stasis for subsidence of swelling, the effect of dampness removing jaundice eliminating also has calculus, and is antibacterial, and antiinflammatory action all has inhibitory action to humoral immunization, cellular immunization.
Herba Bidentis Bipinnatae, formal name used at school Bidens pilosaLinn is Compositae annual herb plant.Be born in wasteland, roadside, hillside and the field of 50~3100 meters of height above sea level; Originate in the torrid zone and subtropical zone (East China, Central China, south China, each provinces and regions, southwest that comprise China) in Asia and America; Be China's medical herbs commonly used among the people, can choose the roguing grass at summer, fall flowering Sheng phase harvesting aerial parts; Using fresh herb or dry is with all herbal medicine.Water decoction that Herba Bidentis Bipinnatae and clerodendron trichotomum are mixed and made into or ethanol preserved material PARA FORMALDEHYDE PRILLS(91,95) property and albumen arthritis all have tangible antiinflammation.Single Herba Bidentis Bipinnatae or clerodendron trichotomum then do not have obvious antiinflammation.
Summary of the invention
The object of the present invention is to provide a kind of Chinese medicine composition.
Another object of the present invention provides a kind of purposes of above-mentioned Chinese medicine composition.
In order to reach above-mentioned purpose, solution of the present invention is:
A kind of Chinese medicine composition comprises treatment active ingredient and pharmaceutically available carrier, it is characterized in that said treatment active ingredient is made by following components in portion by weight: 20~60 parts of Herba Lysimachiaes, 20~60 parts of Herba Bidentis Bipinnatae.
Preferably, the mode below said treatment active ingredient is used makes: get the Herba Lysimachiae and the Herba Bidentis Bipinnatae of above-mentioned weight proportion, the back decocting is pulverized in oven dry, and decocting liquid leaves standstill, and filters, and concentrates, and must treat active ingredient.
Particularly, said treatment active ingredient adopts following mode to make: get 20~60 parts of Herba Lysimachiaes by weight ratio, 20~60 parts of Herba Bidentis Bipinnatae; Oven dry is pulverized, and mixes, and then adds the water of above-mentioned Herba Lysimachiae and 8~20 times of amounts of Herba Bidentis Bipinnatae gross weight; Soak 60~120min; Then decoct and extract 60~120min, decocting liquid leaves standstill, and is subsequent use after filtering; Medicinal residues add the water of 8~20 times of amounts again, decoct to extract 60~120min, and decocting liquid leaves standstill, and filter, and with the filtrate merging first time, concentrate, and must treat active ingredient.
Preferably, said treatment active ingredient comprises following components in portion by weight: 30~40 parts of Herba Lysimachiaes, 30~40 parts of Herba Bidentis Bipinnatae.
In the embodiment that recommends, described Chinese medicine composition is an oral formulations.
In the embodiment that recommends, said oral formulations is tablet, pill, sublimed preparation, powder, granule, powder, capsule, buccal tablet or effervescent tablet.
In the embodiment that recommends; Said carrier includes but not limited to filler, disintegrating agent, binding agent, wetting agent, lubricant, and said filler is starch, dextrin, lactose, sucrose, Icing Sugar, microcrystalline Cellulose, glucose, meglumine, glucosamine, mannitol, calcium sulfate or calcium bisulfate; Disintegrating agent is hyprolose, carboxymethyl starch sodium, polyvinylpolypyrrolidone, cross-linking sodium carboxymethyl cellulose or crosslinked hydroxypropyl methylcellulose; Binding agent is hydroxypropyl methylcellulose sodium or polyvidone; Wetting agent is water or ethanol; Lubricant is magnesium stearate or Pulvis Talci.
In addition, the applicant finds under study for action that also above-mentioned Chinese medicine composition has the purposes of prevention or treatment lithangiuria.
In the embodiment that recommends, said lithangiuria is ureteral calculus or renal calculus.
In the embodiment that recommends, said lithangiuria is calcium oxalate stone, calcium phosphate stone or struvite calculus.
Only if specialize, the implication of employed here all technology and scientific terminology is identical with the affiliated common implication of understanding of technical field those skilled in the art of the present invention.Equally, all introduce the present invention as a reference at this publication of mentioning, patent application, patent and other reference materials.
The present invention adopts and gives SD rat oral gavage 1% amine-oxides and 1% ethylene glycol making kidney of rats calculus pathological model; Then use Herba Lysimachiae and Herba Bidentis Bipinnatae to irritate stomach; Finding that above medicine has alleviates the nephridial tissue edema that causes because of calculus, slows down the damage and the pathological changes of kidney, increases voided volume; Reduce the formation of calculus in the nephridial tissue, and then prevent and treat the effect of renal calculus.Use this pharmaceutical composition of proof clinically and have fast, the difficult recurrence of calculus, but also have the distinguishing feature of relieving spasm to stop pain, oral back is alleviated renal colic fast.
The specific embodiment
Embodiment 1
Get Herba Lysimachiae 20g, Herba Bidentis Bipinnatae 20g, the oven dry pulverizing mixes, and then adds the water of above-mentioned Herba Lysimachiae and 8 times of amounts of Herba Bidentis Bipinnatae gross weight, soaks 60min, then decocts and extracts 60min, and decocting liquid leaves standstill, and the filtration back is subsequent use; Medicinal residues add the water of 8 times of amounts again, and 60min is extracted in decoction, and decocting liquid leaves standstill, and filter, and with the filtrate merging first time, concentrate, and get 4.2g treatment active ingredient.
Embodiment 2
Get Herba Lysimachiae 20g, Herba Bidentis Bipinnatae 60g, the oven dry pulverizing mixes, and then adds the water of above-mentioned Herba Lysimachiae and 20 times of amounts of Herba Bidentis Bipinnatae gross weight, soaks 120min, then decocts and extracts 120min, and decocting liquid leaves standstill, and the filtration back is subsequent use; Medicinal residues add the water of 20 times of amounts again, and 120min is extracted in decoction, and decocting liquid leaves standstill, and filter, and with the filtrate merging first time, concentrate, and get 8.6g treatment active ingredient.
Embodiment 3
Get Herba Lysimachiae 60g, Herba Bidentis Bipinnatae 20g, the oven dry pulverizing mixes, and then adds the water of above-mentioned Herba Lysimachiae and 20 times of amounts of Herba Bidentis Bipinnatae gross weight, soaks 120min, then decocts and extracts 120min, and decocting liquid leaves standstill, and the filtration back is subsequent use; Medicinal residues add the water of 20 times of amounts again, and 120min is extracted in decoction, and decocting liquid leaves standstill, and filter, and with the filtrate merging first time, concentrate, and get 8.5g treatment active ingredient.
Embodiment 4
Get Herba Lysimachiae 30g, Herba Bidentis Bipinnatae 40g, the oven dry pulverizing mixes, and then adds the water of above-mentioned Herba Lysimachiae and 20 times of amounts of Herba Bidentis Bipinnatae gross weight, soaks 120min, then decocts and extracts 120min, and decocting liquid leaves standstill, and the filtration back is subsequent use; Medicinal residues add the water of 20 times of amounts again, and 120min is extracted in decoction, and decocting liquid leaves standstill, and filter, and with the filtrate merging first time, concentrate, and get 7.6g treatment active ingredient.
Embodiment 5
Get Herba Lysimachiae 40g, Herba Bidentis Bipinnatae 30g, the oven dry pulverizing mixes, and then adds the water of above-mentioned Herba Lysimachiae and 12 times of amounts of Herba Bidentis Bipinnatae gross weight, soaks 100min, then decocts and extracts 100min, and decocting liquid leaves standstill, and the filtration back is subsequent use; Medicinal residues add the water of 12 times of amounts again, and 100min is extracted in decoction, and decocting liquid leaves standstill, and filter, and with the filtrate merging first time, concentrate, and get 7.8g treatment active ingredient.
Experimental animal pharmacodynamics provided by the invention, clinical practice result and acute toxicity test concrete grammar step are following:
Test Example 1:Medicine of the present invention is to the control test of renal calculus rat model
Method: adopt ethylene glycol to add ammonium chloride method and induce kidney of rats calculus model, give medicine simultaneously and carry out the intervention treatment, observe the calculus degree of medicine, serum BUN, the influence of Cr content and 24 hours voided volume to kidney of rats calculus model.
1 test material
Animal: the SD rat, the cleaning level, body weight 180~200g, male, health, Shanghai Slac Experimental Animal Co., Ltd..
The treatment active ingredient (trial drug) that obtains among medicine: the embodiment 5, PAISHI KELI contains 11g crude drug/g, Jisheng Pharmaceutical Factory, Nanchang, Jiangxi system.
Reagent: creatinine reagent box, blood urea nitrogen test kit, it is made that bio-engineering research is built up in Nanjing.
Instrument: SpectraMAX M2 ELIASA (Molecular Device company), electronic balance (Mettler Toledo Inc.), operating microscope, thermostat water bath.
2 test methods
2. 1 modeling and index detect
60 of rats, adaptability are divided into 6 groups after raising for 1 week at random, 10 every group, are respectively normal control group, model control group, positive drug (PAISHI KELI) matched group and the large, medium and small dose groups of trial drug.Irritating stomach every day except that the normal control group gives the distilled water 10ml/kg; (every day is all with containing tap water that 1% ethylene glycol adds 1% ammonium chloride as drinking water in all the other 5 groups of rat modelings; Drink to change into drinking separately after a week and contain 1% ethylene glycol); Simultaneously to positive drug control group and the large, medium and small dose groups of trial drug by positive drug control group (6g crude drug/kg), the heavy dose of group of trial drug (6g crude drug/kg), middle dose groups (4g crude drug/kg), small dose group (the dosage gastric infusion of 2g crude drug/kg); Model control group is irritated stomach and is given distilled water, and each treated animal administration capacity is 10ml/kg, continuously modeling and 4 weeks of gastric infusion.Test and carry out 14d, rat docking blood sampling, the centrifuging and taking upper serum is used for biochemical measurement: diacetyl-oxime colorimetry is surveyed serum urea nitrogen (BUN) level, is removed protein method survey creatinine (Crea) level.Test is carried out 28d and is collected each rat 24h urine on an empty stomach respectively with metabolic cage, measures the 24h voided volume.Get the both sides kidney after rat is put to death and weigh, calculate the organ coefficient of kidney.Every rat is got right kidney, and 10% formalin is fixed, and is used for the nephridial tissue pathological examination.
2. 2 nephridial tissue histopathologic examinations
Criterion is following:
0 grade: no crystallization;
1 grade: the renal cortex intercrystalline;
2 grades: the renal medulla intercrystalline;
3 grades: the renal papillae intercrystalline;
4 grades: the renal pelvis intercrystalline.
Be designated as 1,2,3,4 respectively, 5 minutes.Each administration group result of the test and model control group are organized a t inspection statistics and are handled.
3 results
3. 1 trial drug is to the influence of calculus rat blood serum blood urea nitrogen, creatinine.
The result sees table 1.
With the normal control group relatively, renal calculus model group rat blood serum blood urea nitrogen, creatinine significantly increase (P < 0.001); With model control group relatively, the heavy dose of group of trial drug rat blood serum blood urea nitrogen obviously reduces (P < 0.05~0.001) with creatinine level, also obviously reduction of middle dose groups rat blood serum urea nitrogen content (P < 0.05).
Table l trial drug is to the influence of large mouse with renal calculs serum urea nitrogen, creatinine
Figure 378231DEST_PATH_IMAGE002
Compare with model, * P 0.05, * * P < 0.0l, * * * P < 0.001
3. 2 trial drugs are to the influence of calculus rat kidney weight, 24h voided volume, renal calculus degree
The result sees table 2.
With model control group relatively, heavy dose of group kidney coefficient significantly reduces, the 24h voided volume significantly increases (p < 0.05~0.001).Heavy dose of group, middle dose groups renal calculus degree obviously alleviate (p < 0.001).
Table 2 trial drug is to the influence of calculus rat kidney coefficient, 24h voided volume, renal calculus degree
Figure 233055DEST_PATH_IMAGE004
Compare with model, * P 0.05, * * P 0.01, * * * P < 0.001
3.3 trial drug influences calculus kidney of rats histology
Mirror is observed visible down: normal rats kidney surface color is even, and the boundary of cortex medullary substance is clear, no calcium oxalate crystal in the tangent plane; Model control group rat kidney surface irregularity has obvious calcification speckle, forms some bulk granule dress calculus in the renal pelvis; The crystallization of the large, medium and small dose groups nephridial tissue of trial drug then mainly is scattered single kitchen range property and the distribution of local number special mess property; The visible crystallization of positive controls is in renal cortex, medullary substance, nipple and being dispersed in property of renal pelvis place or the assembly of many kitchen ranges property.
3.4 ordinary circumstance is observed
Normal rats hair color gloss, honey stomach, the drinking-water appropriateness, weight increase is very fast, and stool is graininess, and the twenty-four-hour urine amount is normal, and the urine color is yellowish.Modeling is respectively organized rat and lassitude occurred, bradykinesia, and hair is owed gloss, and diet reduces, and activity is few, and hematuria symptom, loose stool appear in indivedual rats.The urine amount then appears in the treatment group to be increased, and spiritual diet activity is normal basically, the mental status of rat in the trial drug group wherein, and active situation, diet and voided volume all are superior to the PAISHI KELI group.
Conclusion
1. trial drug has the effect that prevents and treats the kidney of rats calculus; Its mechanism of action possibly alleviate the damage of renal cells with it and promote its reparation; Strengthen nephridial tissue organelle Stability Analysis of Structures, reduce inflammatory cell infiltration, strengthen pelviureteral wriggling; Quicken urine excretion, enhancing urine mobilization force etc. are relevant.
2. trial drug is basic identical to the preventive and therapeutic effect and the PAISHI KELI of kidney of rats calculus model, but its whole curative effect is superior to PAISHI KELI, and pointing out this medicine is the active drug of preventing and treating renal calculus.
Test Example 2: medicine of the present invention is to the therapeutic test of renal calculus rat model
Method: adopt ethylene glycol to add ammonium chloride method and induce kidney of rats calculus model, give medicine behind the modeling 14d and treat, the viewing test medicine is to the calculus degree of kidney of rats calculus model, the influence of 24 hours voided volume.
1 test material
Animal: the SD rat, the cleaning level, body weight 180~200g, male, health, Shanghai Slac Experimental Animal Co., Ltd..
The treatment active ingredient (trial drug) that obtains among medicine: the embodiment 4, PAISHI KELI contains 11g crude drug/kg, Jisheng Pharmaceutical Factory, Nanchang, Jiangxi system.
Instrument: SpectraMAX M2 ELIASA (Molecular Device company), electronic balance (prunus mume (sieb.) sieb.et zucc. Teller one holder benefit company), operating microscope, thermostat water bath.
2 test methods
2. 1 modeling and index detect
36 of rats, adaptability are divided into 6 groups after raising for 1 week at random, 6 every group, are respectively normal control group, model control group, positive drug (PAISHI KELI) matched group, the large, medium and small dose groups of trial drug.5 groups of rat modelings (every day is all with containing tap water that 1% ethylene glycol adds 1% amine-oxides as drinking water); Stop modeling behind the modeling 14d; The normal control group is irritated stomach and give distilled water 10ml/kg every day; Simultaneously to positive drug control group and the large, medium and small dose groups of trial drug by positive drug control group (6g crude drug/kg), the heavy dose of group of trial drug (6g crude drug/kg), middle dose groups (4g crude drug/kg), small dose group (the dosage gastric infusion of 2g crude drug/kg); Model control group is irritated stomach and is given distilled water, and each treated animal administration capacity is 10ml/kg.Continuous gastric infusion 7d.8d is carried out in test, collects each rat 24h urine on an empty stomach respectively with metabolic cage, measures the 24h voided volume.Get the both sides kidney after rat is put to death and weigh, calculate the organ coefficient of kidney.Every rat is got right kidney, and 10% formalin is fixed, and is used for the nephridial tissue pathological examination.
2.2 nephridial tissue histopathologic examination
Criterion is following:
0 grade: no crystallization;
1 grade: the renal cortex intercrystalline;
2 grades: the renal medulla intercrystalline;
3 grades: the renal papillae intercrystalline;
4 grades: the renal pelvis intercrystalline.
Be designated as 1,2,3,4 respectively, 5 minutes.Each administration group result of the test and model control group are organized a t inspection statistics and are handled.
3 results
3. 1 trial drug is to the influence of calculus rat kidney coefficient, 24h voided volume, renal calculus degree.
The result sees table 3.
With model control group relatively, heavy dose of group kidney coefficient significantly reduces (P < 0.05~0.01), heavy dose of group, middle dose groups renal calculus degree obviously alleviate (P < 0.001).Urine calcium ion and twenty-four-hour urine amount do not have significant change.
Table 3 trial drug is to the influence of calculus rat kidney coefficient, 24h voided volume, renal calculus degree
Figure 12792DEST_PATH_IMAGE006
Compare with model, * P 0.05, * * P 0.01, * * * P < 0.001
3.2 trial drug influences calculus kidney of rats histology
Mirror is observed visible down: normal rats kidney surface color is even, and the boundary of cortex medullary substance is clear, no calcium oxalate crystal in the tangent plane; Model control group rat kidney surface irregularity has obvious calcification speckle, and nephridial tissue changes and mainly forms the crystallization of many kitchen ranges property at renal medulla cone collecting tubule and renal papillae place; The crystallization of the large, medium and small dose groups nephridial tissue of trial drug then mainly is scattered single kitchen range property and the distribution of local number special mess property; The visible crystallization of positive control elder sister is in renal cortex, medullary substance, nipple and being dispersed in property of renal pelvis place or the assembly of many kitchen ranges property.
3.3 ordinary circumstance is observed
Normal rats hair color gloss, honey stomach, the drinking-water appropriateness, weight increase is very fast, and stool is graininess, and the twenty-four-hour urine amount is normal, and the urine color is yellowish.Modeling is respectively organized rat and lassitude occurred, bradykinesia, and hair is owed gloss, and diet reduces, and activity is few, loose stool.The then spiritual diet activity of treatment group is normal basically.
Conclusion
1 trial drug can reduce the formation of calculus in the nephridial tissue, and the kidney of rats calculus is had obvious therapeutic action.
2 these medicines are basic identical to the therapeutical effect and the PAISHI KELI of kidney of rats calculus model.
Test Example 3: the The acute toxicity tests report
The amounts of reactants of test determination is: the maximum dosage-feeding test
Maximum dosage-feeding test is meant in single or the 24h the maximum dosage that repeatedly (2~3 times) administration is adopted.The maximum dosage-feeding test is meant and under the condition of rational administration concentration and rational administration capacity, gives experimental animal with the maximal dose that allows, observes the reaction that animal occurs.
1 test method
1.1 tried thing
The mixing water that is tried thing and the be Herba Lysimachiae+Herba Bidentis Bipinnatae liquid of boiling medicine.
Method for distilling: Herba Lysimachiae 100g+ Herba Bidentis Bipinnatae 100g, add water 4000ml (1:20) after the mixing and carry out the decocting extraction, to filter, filtrating is deposited fully; Medicinal residues add with water by volume the same terms extraction 1 time, filter, and merge and vacuum concentration with the 1st extracting solution, get dry thing 26g.
Reagent preparation: adopt dissolved in distilled water, be made into the drug solution that maximum meltage is 1.73g/ml.
Being converted into the crude drug dosage is: 266.67g crude drug/kg body weight.
1.2 experimental animal
Adopt healthy adult KM mice, male and female half and half.Average weight 25g.The initial body weight of animal is no more than average weight ± 20%.
1.3 test is divided into groups
This test is provided with 2 groups, and 10 every group, male and female half and half are divided into blank control group, administration group at random.
Irritate 3 distilled water solutions of stomach in blank control group: the 24h.
Irritate stomach in administration group: the 24h and receive reagent thing solution for 3 times.
1.4 route of administration
Take the method for gastric infusion.
1.5 administration capacity
It is 20ml/kg that gastric infusion, mice are irritated the stomach amount at every turn.
1.6 observe the time limit
Be 14 days observing time.
1.7 observation index
Comprise the weight of animals variation, diet, outward appearance, behavior, secretions, Excreta, death condition and toxic reaction (symptom of toxic reaction, the order of severity, zero-time, persistent period, whether reversible) etc.Dying and dead animal are in time dissected, and other animals are dissected after the observation period finishes, the change of observation animal organ's volume, color, quality.
2 interpretations of result
All there is not death 2.1 respectively organize mice.
2.2 diet: it is all normal that each organizes the mice diet situation.
2.3 outward appearance: each organizes mice hair color and glossiness no significant difference, does not have perpendicular hair, depilation phenomenon, no edema or erythema, and prompting is not had obviously renal function by the reagent thing to be influenced, skin not to be produced inflammation, allergic phenomena.
2.4 breathe: each organize mice all do not have pant, the cyanosis phenomenon, prompting receive the reagent thing to respiratory center, cardio-pulmonary function does not have obviously influences.
2.5 behavior: it is normal that each organizes the mice behavior, atremia, clonicity tic, tonic convulsion, dusk fault property tic, and no opisthotonus does not have irascible behavior.Prompting receive the reagent thing to central nervous system, breathing, neuromuscular, autonomic nerve does not have obviously influences.
2.6 the pain sensation: each organizes the equal analgesia forfeiture of mice phenomenon.
2.7 vomiting: each organizes mice does not all have vomiting or retch phenomenon.
2.8 secretions: it is all normal that each organizes mice, do not have the moist phenomenon of mouthful peritricha.
2.9 Excreta: administration occurred voiding excreta moist glutinous greasy the same day, and stool colour is a brown, no polyuria, redly urinate, the urinary incontinence phenomenon.After this drain normal.
2.10 dissect:
Liver: the liver color and luster has no significant change, and does not have obvious enlargement and form and changes.
Kidney: kidney does not have the edema phenomenon, does not have obviously to change.
Heart: do not have obviously change.
Lungs: do not have obviously change.
Spleen: do not have obvious ripple and become.
Conclusion: receive the reagent thing in this maximum dosage-feeding test, the KM mice is not produced tangible toxicity phenomenon.
Test Example 4: the clinical treatment result
Complete documentation treatment renal calculus patient 62 people (calculus of urethra 23 people wherein, two renal calculus 24 people, single renal calculus 15 people are arranged at present.These patients have B ultrasonic/X line to take the photograph sheet as the contrast before and after the treatment).
Everyone takes this medical herbs (weight proportion of Herba Lysimachiae and Herba Bidentis Bipinnatae is 1:1) and pulverizes the powder of processing (60g/ bag), and wrap every day one, and decocting is repeatedly worked as tea-drinking, two courses of treatment Monday, shared two courses of treatment.
The result: renal calculus effective percentage first course of treatment accounts for 80% (containing two renal calculuss), second the course of treatment effective percentage be more than 90%.Calculus of urethra effective percentage first course of treatment is 95%.
In addition, this decoct also has the distinguishing feature of relieving spasm to stop pain, and renal colic can be alleviated in 5~10 minutes in oral back.
Model case:
Bag X, man, 30 years old.Suffered from right renal calculus 3 years, ultrasound diagnosis finding " right side renal calculus (the about 5mm*4mm of size), companion's sinus renalis slightly separates " is taken 2 weeks of this medicine, and calculus excretes.Check B ultrasonic once more, do not see obviously unusual.
Old X, man, 46 years old.Suffer from 2 weeks of ureteral calculus, pain unbearably, ultrasound diagnosis finding " left ureter basin section calculus, the about 4mm*6mm of size ", pain disappears half an hour behind oral the medicine, one week the back calculus per urethram excrete, check B ultrasonic once more, recover normally.
In sum; The present invention shows through a large amount of experimental studies; The Chinese herbal medicine formula of being made up of Herba Lysimachiae and Herba Bidentis Bipinnatae has and alleviates the nephridial tissue edema that causes because of calculus, slows down the damage and the pathological changes of kidney, increases voided volume; Reduce the formation of calculus in the nephridial tissue, and then can prevent or treat renal calculus.In the maximum dosage-feeding test, the KM mice is not produced tangible toxicity phenomenon.This decoct of clinical practice proof has fast, the difficult recurrence of calculus, but also has the distinguishing feature of relieving spasm to stop pain, and oral back is alleviated renal colic fast.
Above Chinese herbal medicine formula is evident in efficacy, and safety range is big, and technology is simple, and integrated cost is low, is a kind of medicine that can be used for preventing and mooring the renal calculus of treatment.
The foregoing description is a preferred implementation of the present invention; But embodiment of the present invention is not restricted to the described embodiments; Other any do not deviate from change, the modification done under spirit of the present invention and the principle, substitutes, combination, simplify; All should be the substitute mode of equivalence, be included within protection scope of the present invention.

Claims (9)

1. a Chinese medicine composition comprises treatment active ingredient and pharmaceutically available carrier, it is characterized in that said treatment active ingredient is made by following components in portion by weight: 20~60 parts of 20~60 parts of Herba Lysimachiaes and Herba Bidentis Bipinnatae.
2. according to the Chinese medicine composition described in the claim 1, it is characterized in that: the mode below said treatment active ingredient is used makes: get the Herba Lysimachiae and the Herba Bidentis Bipinnatae of above-mentioned weight proportion, the back decocting is pulverized in oven dry; Decocting liquid leaves standstill; Filter, concentrate, must treat active ingredient.
3. according to the Chinese medicine composition described in the claim 1, it is characterized in that: said treatment active ingredient comprises following components in portion by weight: 30~40 parts of Herba Lysimachiaes, 30~40 parts of Herba Bidentis Bipinnatae.
4. according to the Chinese medicine composition described in the claim 1, it is characterized in that: described Chinese medicine composition is an oral formulations.
5. according to the Chinese medicine composition described in the claim 4, it is characterized in that: said oral formulations is tablet, pill, sublimed preparation, powder, granule, powder, capsule, buccal tablet or effervescent tablet.
6. according to the Chinese medicine composition described in the claim 1; It is characterized in that: said carrier includes but not limited to filler, disintegrating agent, binding agent, wetting agent, lubricant, and said filler is starch, dextrin, lactose, sucrose, Icing Sugar, microcrystalline Cellulose, glucose, meglumine, glucosamine, mannitol, calcium sulfate or calcium bisulfate; Disintegrating agent is hyprolose, carboxymethyl starch sodium, polyvinylpolypyrrolidone, cross-linking sodium carboxymethyl cellulose or crosslinked hydroxypropyl methylcellulose; Binding agent is hydroxypropyl methylcellulose sodium or polyvidone; Wetting agent is water or ethanol; Lubricant is magnesium stearate or Pulvis Talci.
7. claim 1 or 2 or 3 or 4 or 5 or 6 the Chinese medicine composition purposes in preparation prevention or treatment lithangiuria medicine.
8. according to the purposes described in the claim 7, it is characterized in that: said lithangiuria is ureteral calculus or renal calculus.
9. according to the purposes described in the claim 7, it is characterized in that: said lithangiuria is calcium oxalate stone, calcium phosphate stone or struvite calculus.
CN2012101460639A 2012-05-14 2012-05-14 Traditional Chinese medicine composition and application thereof Pending CN102670705A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN2012101460639A CN102670705A (en) 2012-05-14 2012-05-14 Traditional Chinese medicine composition and application thereof

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN2012101460639A CN102670705A (en) 2012-05-14 2012-05-14 Traditional Chinese medicine composition and application thereof

Publications (1)

Publication Number Publication Date
CN102670705A true CN102670705A (en) 2012-09-19

Family

ID=46803691

Family Applications (1)

Application Number Title Priority Date Filing Date
CN2012101460639A Pending CN102670705A (en) 2012-05-14 2012-05-14 Traditional Chinese medicine composition and application thereof

Country Status (1)

Country Link
CN (1) CN102670705A (en)

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
汤迎爽等: "鬼针草的化学成分与药理作用研究进展", 《中医药导报》 *

Similar Documents

Publication Publication Date Title
CN101406635B (en) Chinese medicine decoction for treating stranguria and eliminating stone
KR100743979B1 (en) Herbal composition for treatment of chronic renal failure and method to produce thereof
CN101757591B (en) Traditional Chinese medicine composition for treating chronic colitis and protitis
CN109224039B (en) Chinese medicinal composition for treating kidney fibrosis and tonifying kidney
CN101317881A (en) Traditional Chinese Medicine Shencha Paishi Compound and Its Preparation
CN102106993B (en) Traditional Chinese medicine composition for treating fatty liver and preparation method thereof
CN101433649A (en) Composition for treating gall stone symptom
CN102670705A (en) Traditional Chinese medicine composition and application thereof
CN104971319B (en) A kind of drug and preparation method thereof for treating kidney stone
CN108686102A (en) A kind of Chinese medicine composition for treating gout
CN107693732A (en) A kind of pharmaceutical composition for treating hypertensive nephropathy and preparation method thereof
CN102895444A (en) Traditional Chinese medicine composition for treating lithangiuria
CN106963912A (en) It is a kind of to treat dalbergia wood compound of eczema and preparation method thereof
CN102552767B (en) Traditional Chinese medicine for treating kidney stone, preparation method and administration mode
CN102949458A (en) Traditional Chinese medicine composition for treating or preventing lithangiuria, and applications thereof
CN100367997C (en) Medicine for treating arthrolithiasis and preparing method thereof
CN104800675A (en) Medicament for treating active ulcerative colitis
CN103948767A (en) Pharmaceutical composition for treating cardiovascular and cerebrovascular diseases, as well as preparation method and application thereof
CN110463799A (en) A kind of wild plant composition of protect liver constipation-relieving tea
CN116712472B (en) Traditional Chinese medicine composition for treating urinary calculus, preparation method and application thereof
CN102836365A (en) Chinese medicinal composition for treating urinary system calculi and application thereof
CN105749021A (en) Chinese medicine preparation for treating chronic glomerulonephritis
CN117462611A (en) A traditional Chinese medicine composition for treating early diabetic nephropathy and its preparation method
CN101601840A (en) A kind of medicine for the treatment of hepatolenticular degeneration
CN106038812A (en) Traditional Chinese medicine capsule for reducing blood fat and removing atherosclerotic plaque

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
ASS Succession or assignment of patent right

Owner name: ZHENG HUAGUI

Free format text: FORMER OWNER: ZHANG ZICHENG

Effective date: 20130221

C41 Transfer of patent application or patent right or utility model
C53 Correction of patent of invention or patent application
CB03 Change of inventor or designer information

Inventor after: Zheng Huagui

Inventor after: Zhang Zicheng

Inventor after: Jin Xin

Inventor after: Su Zhengqin

Inventor before: Zhang Zicheng

Inventor before: Zheng Huagui

Inventor before: Jin Xin

Inventor before: Su Zhengqin

COR Change of bibliographic data

Free format text: CORRECT: INVENTOR; FROM: ZHANG ZICHENG ZHENG HUAGUI JIN XIN SU ZHENGQIN TO: ZHENG HUAGUI ZHANG ZICHENG JIN XIN SU ZHENGQIN

TA01 Transfer of patent application right

Effective date of registration: 20130221

Address after: Town Park Road 355400 Ningde City Zhouning County in Fujian province No. 8 Lions

Applicant after: Zheng Huagui

Address before: The source of the town of Ningde city in Fujian province 355400 Zhouning County Pu Yang Cun 85 Road No. 25

Applicant before: Zhang Zicheng

C12 Rejection of a patent application after its publication
RJ01 Rejection of invention patent application after publication

Application publication date: 20120919